MetaVia Advances Obesity Drug with Higher-Dose Phase 1 Trial
Event summary
- MetaVia dosed the first patient in Part 3 of its Phase 1 trial for DA-1726, evaluating 48 mg and 64 mg titration regimens.
- The company reported 9.1% weight loss and improved glucose control in the 48 mg cohort of its Phase 1 trial.
- MetaVia closed a $9.3 million public offering in January 2026, providing capital for ongoing studies.
- The company expects to report data from the Phase 1 Part 3 trial in the fourth quarter of 2026.
The big picture
MetaVia's progress with DA-1726 underscores the competitive push for next-generation obesity treatments with dual GLP-1/glucagon mechanisms. The company's strategic focus on optimizing titration regimens could differentiate it from existing therapies, but success hinges on maintaining favorable safety profiles. With a strengthened IP portfolio and ongoing AI-driven collaborations, MetaVia is positioning itself in the rapidly evolving cardiometabolic space, where liver and metabolic disease treatments are increasingly converging.
What we're watching
- Clinical Efficacy
- Whether DA-1726's higher-dose regimens can sustain superior weight loss and glucose control without compromising safety.
- Regulatory Pathway
- The pace at which MetaVia can advance vanoglipel through end-of-Phase 2 meetings with the FDA.
- Financial Runway
- How MetaVia's $13.7 million cash position will support operations through the anticipated data readout in Q4 2026.
Related topics